About
Alzheimer's Antibody Treatments
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBiotech
Team (9)
Clinical Trials (12)
View allTotal Trials
12
As Lead Sponsor
10
As Collaborator
2
Total Enrollment
1,701
By Phase
PHASE2: 6PHASE3: 2PHASE1: 4
By Status
COMPLETED: 6ACTIVE_NOT_RECRUITING: 2TERMINATED: 2RECRUITING: 1ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline12 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT07105709Collaborator
Open-label Extension Study in Participants With Early Alzheimer's Disease
PHASE2Recruiting
297 participants
Started: Aug 14, 2025 · Completed: Nov 24, 2028
NCT06111014Lead Sponsor
Continuation Study for Latozinemab
PHASE3Enrolling by invitation
35 participants
Started: Dec 8, 2023 · Completed: Nov 30, 2027
NCT06079190Collaborator
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
PHASE2Active, not recruiting
367 participants
Started: Oct 20, 2023 · Completed: Nov 23, 2026
NCT05744401Lead Sponsor
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
PHASE2Terminated
198 participants
Started: Jan 4, 2023 · Completed: Jan 31, 2025
NCT05053035Lead Sponsor
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
PHASE2Terminated
5 participants
Started: Sep 2, 2021 · Completed: Oct 28, 2022
Locations (1)
Headquarters
South SF, CA, United States
Map
Loading map...